1. Introduction {#sec1-antibodies-05-00012}
===============

Anti-phospholipid (APL) antibodies are a heterogeneous group of autoantibodies targeting different phospholipid binding protein antigens. These autoantibodies include lupus anti-coagulant (LAC), anti-cardiolipin (aCL), anti-beta 2 glycoprotein 1 (anti-β~2~GP1), and anti-prothrombin antibodies \[[@B1-antibodies-05-00012]\]. APL antibodies dysregulate normal cellular activities and are associated with recurrent thrombosis (venous, arterial, and microvascular), pregnancy complications (e.g., obstetric failure, pre-eclampsia and eclampsia), and non-specific manifestations (e.g., thrombocytopenia, heart valve disease, chorea, livedo reticularis/racemosa, and nephropathy) \[[@B2-antibodies-05-00012]\]. APL antibodies are also present in 1%--5% of healthy populations, including children \[[@B3-antibodies-05-00012],[@B4-antibodies-05-00012]\]. These populations appear to be asymptomatic, since their autoantibodies are associated with low reactivity \[[@B4-antibodies-05-00012]\].

Persistently high levels of APL antibodies, together with specific clinical manifestations, are required for the diagnosis of antiphospholipid syndrome (APS) \[[@B1-antibodies-05-00012]\]. APS can occur in isolation or in association with underlying autoimmune diseases such as systemic lupus erythematosus (SLE). The Sydney criteria for the diagnosis of APS recommend that three standard diagnostic assays are used to detect APL antibodies \[[@B5-antibodies-05-00012]\]. These diagnostic assays include two enzyme-linked immunosorbent assays (ELISA) that directly detect APL antibodies binding to cardiolipin-β~2~GP1 complexes, or β~2~GP1 only. The third is a clotting assay which indirectly detects APL antibodies by measuring their functional effects on the coagulation system (LAC activity, [Table 1](#antibodies-05-00012-t001){ref-type="table"}) \[[@B1-antibodies-05-00012],[@B3-antibodies-05-00012],[@B6-antibodies-05-00012]\]. Although these assays detect overlapping subpopulations of autoantibodies, their correlation with the clinical manifestations of APS can be varied. LAC assays are superior for detecting pathological subpopulations of APL antibodies when the quality of plasma is maintained \[[@B7-antibodies-05-00012]\]. ELISAs for aCL and anti-β~2~GP1 antibodies, however, are weakly associated with thrombotic complications. This may be due to poor standardisation of assays, variable sources and the integrity of β~2~GPI, the secondary calibration process, and/or the assessment and derivation of cut-off values \[[@B8-antibodies-05-00012]\]. Consequently, a combination of these tests is used to determine the clinical risk. Patients with persistently high APL antibodies titres (positive in ELISA) and positive LAC activities on at least two occasions, 12 weeks apart, are at higher risk of thrombosis and/or pregnancy complications \[[@B1-antibodies-05-00012]\].

The criteria for the diagnosis of APS are well established, yet the interactions between APL antibodies, targeted antigens, and receptors remain unclear. Anti-β~2~GP1 antibodies and their target, β~2~GP1, have become a focus of research for their potential role in thrombosis and pregnancy complications \[[@B9-antibodies-05-00012]\]. β~2~GP1-dependent LAC antibodies demonstrate a stronger correlation with thrombosis compared to β~2~GP1-independent LAC antibodies \[[@B10-antibodies-05-00012],[@B11-antibodies-05-00012]\]. Similarly, β~2~GP1-dependent aCL antibodies are more highly associated with APL antibodies-related complications compared to transient β~2~GP1-independent aCL antibodies induced by infections \[[@B12-antibodies-05-00012]\]. Many potential mechanisms of interaction between anti-β~2~GP1 antibodies, β~2~GP1, and cells---e.g., platelets, endothelial cells and monocytes---have been suggested \[[@B13-antibodies-05-00012]\]. However, studies investigating the effects of anti-β~2~GP1 antibodies and β~2~GP1 on platelets \[[@B14-antibodies-05-00012],[@B15-antibodies-05-00012],[@B16-antibodies-05-00012]\] may help lead to an improved understanding of their interactions, and consequently, their impact on the haemostatic system \[[@B17-antibodies-05-00012]\]. Activation of platelet receptor(s)/metabolic pathway(s) by anti-β~2~GP1 antibodies and β~2~GP1 may result in excessive clot formation and potentially initiate thrombosis and/or pregnancy complications \[[@B14-antibodies-05-00012],[@B15-antibodies-05-00012],[@B16-antibodies-05-00012]\]. Therefore, this review discusses the current understanding of the characteristics and interactions between β~2~GP1 and anti-β~2~GP1 antibodies in relation to platelet receptors and function.

2. β~2~GP1 {#sec2-antibodies-05-00012}
==========

APL antibodies were originally thought to bind directly to phospholipids \[[@B26-antibodies-05-00012]\]. In the 1990s, three independent groups demonstrated that APL antibodies actually interacted with phospholipids via β~2~GP1 \[[@B27-antibodies-05-00012],[@B28-antibodies-05-00012],[@B29-antibodies-05-00012]\], significantly raising the interest in this protein. β~2~GP1 had been discovered earlier in 1961 \[[@B30-antibodies-05-00012]\], and its amino acid sequence determined in 1984 \[[@B31-antibodies-05-00012]\]. It was misnamed apolipoprotein H \[[@B32-antibodies-05-00012]\], since it is not an integral part of lipoproteins. Once synthesised in the liver and placenta, β~2~GP1 circulates in blood at a concentration of approximately 4--5 μM. Blood levels of β~2~GP1 are higher in older individuals and in patients with APS, but are lower in pregnant women and patients with stroke and myocardial infarction \[[@B33-antibodies-05-00012]\].

β~2~GP1 is an evolutionarily conserved single chain anionic phospholipid-binding glycoprotein, with a molecular weight of approximately 43 kDa \[[@B34-antibodies-05-00012],[@B35-antibodies-05-00012],[@B36-antibodies-05-00012]\]. It belongs to the complement control protein superfamily \[[@B37-antibodies-05-00012]\] and consists of 326 amino acids that are arranged in five short consensus repeat, termed "sushi" domains \[[@B31-antibodies-05-00012],[@B38-antibodies-05-00012],[@B39-antibodies-05-00012]\]. The first four domains, each comprising approximately 60 amino acids, are conserved sequences linked together by two disulfide bridges. The fifth domain (DV), however, is a modified form with 82 amino acids. It contains a six residue insertion, a 19-amino acid C-terminal extension and an additional disulfide bond that includes a C-terminal cysteine. These positively charged lysine-rich amino acids (282--287) determine the affinity of β~2~GP1 for anionic phospholipids and negatively charged molecules. DV also adopts a flexible hydrophobic loop (amino acids 311--317), containing a Trp-Lys sequence which is potentially able to insert into membranes. β~2~GP1 has four N-glycosylation sites (Arg143, Arg 164, Arg 174, and Arg 234) located in third domain (DIII) and fourth domain (DIV). There is also one O-linked sugar on Thr130 in β~2~GP1 that accounts for approximately 20% *w/w* of the total molecular mass \[[@B40-antibodies-05-00012]\].

2.1. Conformations of β~2~GP1 {#sec2dot1-antibodies-05-00012}
-----------------------------

β~2~GP1 adopts many post-translational modifications which alter the structure and function of the molecule and the exposure of the cryptic epitope \[[@B41-antibodies-05-00012]\]. Among them, three interchangeable conformations are more commonly reported ([Figure 1](#antibodies-05-00012-f001){ref-type="fig"}). The first conformation was reported by two groups \[[@B38-antibodies-05-00012],[@B42-antibodies-05-00012]\] based on the crystal structure of the protein. In this conformation, first four domains are stretched with DV at a right angle to the other domains, resembling a J-shape, fish-hook or 'hockey stick' conformation. The second reported conformation is S-shaped, as demonstrated using small-angle X-ray scattering \[[@B43-antibodies-05-00012]\]. This conformation contains carbohydrate chains from DIII--IV that are twisted and positioned on DI. The third conformation is a common 'closed' circular formation present in plasma where DI interacts with DV. This circular formation was initially proposed by Koike *et al.* in 1998 \[[@B44-antibodies-05-00012]\], and later directly visualised by Agar *et al.* (2010) using electron microscopy \[[@B41-antibodies-05-00012]\].

### 2.1.1. Transformation between β~2~GP1 Conformations {#sec2dot1dot1-antibodies-05-00012}

The discovery of three interchangeable β~2~GP1 structures led to increased understanding of the interaction between anti-β~2~GP1 antibodies and β~2~GP1. These conformational alterations determine the exposure of the cryptic epitope which includes arginine 39--arginine 43 (R39--R43), DI--II interlinker, and possibly aspartic acid residues at positions 8 and 9 \[[@B45-antibodies-05-00012]\]. Anti-domain-I-β~2~GP1 (anti-DI-β~2~GP1) antibodies targeting this discontinuous epitope are highly associated with APL antibodies-related clinical manifestations \[[@B46-antibodies-05-00012],[@B47-antibodies-05-00012]\].

β~2~GP1 is suggested to circulate in an S-shaped or a circular conformation, with less than 0.1% of β~2~GP1 in circulation present in the J-shaped conformation \[[@B41-antibodies-05-00012],[@B47-antibodies-05-00012]\]. The cryptic epitope in both S-shaped and circular β~2~GP1 is shielded by carbohydrate chains positioned on top of DI \[[@B43-antibodies-05-00012],[@B48-antibodies-05-00012]\]. In circular β~2~GP1, these negatively-charged carbohydrate chains are also proposed to neutralise the positively-charged DI, allowing the binding of DV \[[@B47-antibodies-05-00012]\]. Therefore, S-shaped β~2~GP1 may represent an intermediate form of the molecule as it transforms from a circular to J-shaped conformation \[[@B47-antibodies-05-00012]\]. When positively charged amino acids and hydrophobic loop in DV interact with anionic surfaces, β~2~GP1 opens out to the J-shaped conformation, breaking the shield on DI and exposing the cryptic epitope \[[@B41-antibodies-05-00012]\].

### 2.1.2. Factors Affecting β~2~GP1 Conformation {#sec2dot1dot2-antibodies-05-00012}

The conformation of β~2~GP1 is dependent on its interaction with anionic surfaces. Its affinity decreases in the presence of ethylene-diamine-tetra-acetic acid (EDTA) \[[@B49-antibodies-05-00012]\], and high concentrations of bivalent cations---e.g., calcium and magnesium ions \[[@B50-antibodies-05-00012]\]. β~2~GP1 that has been cleaved at DV is also known to have lower affinity \[[@B51-antibodies-05-00012]\]. Conversely, dimerisation \[[@B52-antibodies-05-00012]\] and increasing β~2~GP1 concentration \[[@B50-antibodies-05-00012]\] elevate its affinity. Besides exposure to anionic surfaces, alternations to pH and salt concentration *in vitro* allow structural transformation of β~2~GP1 \[[@B41-antibodies-05-00012]\]. High pH and salt concentrations convert circular β~2~GP1 into the J-shaped conformation, and *vice versa* at a low pH and salt concentration. It has also been speculated that these alterations in pH and salt concentration possibly affect the hydrophilic interaction that may be present between DI and DV \[[@B41-antibodies-05-00012]\].

APS patients have been proposed to have higher oxidative stress compared to healthy individuals \[[@B53-antibodies-05-00012]\]. Oxidative stress favours disulfide bonding between Cys32 and Cys60 (located at DI) and within Cys288 and Cys326 (located at DV) of β~2~GP1. These bonds potentially encourage the binding of anti-β~2~GP1 antibodies to β~2~GP1, and might lead to thrombus formation. Oxidation and biotinylation of β~2~GP1 glycan chains also induce β~2~GP1 dimerisation, which raises β~2~GP1 affinity \[[@B54-antibodies-05-00012]\]. Additionally, it is speculated that the intramolecular interaction and conformation of β~2~GP1 can be affected by increased sialylation of β~2~GP1 glycan structures \[[@B55-antibodies-05-00012]\].

Lastly, the structure of β~2~GP1 can be inherently diverse. Among the four allelic variants, β~2~GP1 Val/Val genotypes were frequently found to co-exist with anti-β~2~GP1 antibodies \[[@B56-antibodies-05-00012]\]. It has also been proposed that the Val247 variant of circular-β~2~GP1 is easier to transform into J-shaped β~2~GP1 after losing the electrostatic interaction between Glu228 (located in DIV) and Lys308 (located in DV) \[[@B57-antibodies-05-00012]\]. Thus, this transformation exposes the cryptic epitope for antibody binding and raises the risk of thrombosis.

2.2. Physiological Role(s) of β~2~GP1 {#sec2dot2-antibodies-05-00012}
-------------------------------------

The precise physiological role of β~2~GP1 is unknown. β~2~GP1-deficient individuals appear to be healthy, suggesting that β~2~GP1 function might not be essential for life \[[@B58-antibodies-05-00012]\]. However, the disulphide bonds and phospholipid binding sites in β~2~GP1 are highly conserved across the animal kingdom \[[@B36-antibodies-05-00012]\]. Therefore, it is very unlikely that this abundant and well-conserved molecule exists without a function.

Although β~2~GP1-deficient individuals do not have an associated haemostatic abnormality, many functions in the regulation of haemostasis have been attributed to β~2~GP1. First, β~2~GP1 has been demonstrated to inhibit adenosine diphosphate (ADP)-mediated platelet aggregation and serotonin secretion \[[@B59-antibodies-05-00012],[@B60-antibodies-05-00012]\]. Second, β~2~GP1 might be a mediator for von Willebrand factor (vWF) activation and clearance. β~2~GP1 has been reported to bind to the A1-domain of vWF, preferably vWF in a glycoprotein (GP) Ib-binding conformation. This low affinity binding allows the formation of disulfide bridges between β~2~GP1 and vWF. Thus, the disulfide bridges prevent vWF-mediated platelet activation \[[@B15-antibodies-05-00012]\] and potentially protect the cleavage of vWF by the vWF protease, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) \[[@B61-antibodies-05-00012]\]. Thirdly, β~2~GP1 has also been demonstrated to be involved in several coagulation pathways, yet these effects remain to be elucidated \[[@B60-antibodies-05-00012]\].

β~2~GP1 has been suggested to be a general scavenger in circulation \[[@B62-antibodies-05-00012],[@B63-antibodies-05-00012]\]. During apoptosis or cellular activation, the reorganisation of the plasma membrane exposes phosphatidylserine on the cell surface. β~2~GP1 binds to phosphatidylserine expressed on these apoptotic cells \[[@B62-antibodies-05-00012]\], as well as platelet microparticles \[[@B63-antibodies-05-00012]\], to assist their phagocytosis by macrophages. In addition, β~2~GP1 is also involved in innate immunity as demonstrated by the insertion of DV of β~2~GP1 into bacterial membranes that can lead to cytosol leakage and death of bacteria \[[@B64-antibodies-05-00012]\]. β~2~GP1 also changes its conformation while binding to lipopolysaccharide on Gram-negative bacteria, forming a complex which allows recognition and clearance by monocytes \[[@B65-antibodies-05-00012]\]. Finally, β~2~GP1 might be important in embryonic development, as the percentage of null offspring born in β~2~GP1 knock-out mice is lower than expected \[[@B66-antibodies-05-00012]\].

In summary, β~2~GP1 has been proposed to be involved in a range of physiological processes, including clot formation, fibrinolysis, cell activation, immune responses, atherosclerosis, apoptosis, angiogenesis, and fetal loss \[[@B60-antibodies-05-00012]\]. Further research is clearly warranted to determine the precise physiological role(s) of β~2~GP1.

3. Anti-β~2~GP1 Antibodies {#sec3-antibodies-05-00012}
==========================

By itself, β~2~GP1 has no deleterious effect on normal cellular function, but rather interferes with the physiological function of cells following binding with anti-β~2~GP1 antibodies. Therefore, it has been proposed that anti-β~2~GP1 antibodies induce a new function for β~2~GP1 \[[@B67-antibodies-05-00012]\]. The affinity of β~2~GP1 is low and only binds to anionic phospholipids below a certain concentration \[[@B41-antibodies-05-00012],[@B48-antibodies-05-00012]\]. Upon binding with anionic phospholipids, it transforms into the J-shaped conformation and exposes the cryptic epitope located at DI which enables antibodies to bind. When the amount of β~2~GP1 bound to anionic phospholipid membrane reaches a certain density, antibodies dimerise the adjacent β~2~GP1 molecules \[[@B48-antibodies-05-00012]\]. This dimerisation forms a high affinity anti-β~2~GP1-β~2~GP1 complex, activating targeted cells and causing APL antibodies-related manifestations.

3.1. Clinical Significance of Anti-β~2~GP1 Antibodies {#sec3dot1-antibodies-05-00012}
-----------------------------------------------------

The presence of anti-β~2~GP1 antibodies, especially those with LAC activity, is highly associated with increased thrombotic risk compared to other APL antibody subgroups \[[@B10-antibodies-05-00012],[@B11-antibodies-05-00012]\]. APS patients have higher levels of platelet activation as reflected by raised urinary thromboxane metabolites \[[@B68-antibodies-05-00012]\]. Moreover, the co-existence of J-shaped β~2~GP1 and anti-β~2~GP1 antibodies prolongs the activated partial thromboplastin time of normal plasma, compared to J-shaped β~2~GP1 alone \[[@B41-antibodies-05-00012]\], suggesting that anti-β~2~GP1 antibodies also affect secondary haemostasis. Conversely, 40% of APS patients have a prolonged bleeding time without an accompanying bleeding tendency \[[@B69-antibodies-05-00012]\]. Although there is no clear explanation for these contradictory findings, it suggests that anti-β~2~GP1 antibodies affect normal haemostatic function.

The contribution of anti-β~2~GP1 antibodies to placental-related pregnancy complications remains controversial. A systematic review and meta-analysis reported that there were insufficient data to support an association between anti-β~2~GP1 antibodies and pregnancy complications \[[@B70-antibodies-05-00012]\]. However, an *in vitro* study demonstrated that anti-β~2~GP1 antibodies stimulate trophoblasts to increase secretion of vascular endothelial growth factor, placental growth factor, and soluble endoglin, leading to a higher risk of obstetrical complication \[[@B71-antibodies-05-00012]\]. Furthermore, anti-β~2~GP1-β~2~GP1 complexes have been suggested to disrupt the anticoagulant shield formed by annexin A5 on vascular cells \[[@B72-antibodies-05-00012]\]. Thus, patients could be predisposed to placental thrombosis that may result in fetal growth restriction and/or pregnancy loss.

3.2. Etiology of Anti-β~2~GP1 Antibodies {#sec3dot2-antibodies-05-00012}
----------------------------------------

The etiology of anti-β~2~GP1 antibodies remains unclear. Both genetic and environmental factors may contribute to their production \[[@B2-antibodies-05-00012],[@B73-antibodies-05-00012]\]. Various animal models and family/population studies have indicated that several human leukocyte antigen genes are associated with the occurrence of APL antibodies and the development of thrombosis \[[@B74-antibodies-05-00012],[@B75-antibodies-05-00012],[@B76-antibodies-05-00012]\]. These pathogenic antibodies are thought to be produced by activated auto-reactive T and B cells due to the similarity between foreign and self-protein/peptide sequences (molecular mimicry) \[[@B77-antibodies-05-00012]\]. Viruses, bacteria, mycoplasma and parasites with the same amino acid sequences can also initiate antibody production \[[@B78-antibodies-05-00012]\]. However, this theory is unable to clearly explain the etiology, as antibodies are also produced by injecting anionic phospholipids such as cardiolipin, phosphatidylserine, or lipopolysaccharide into animals \[[@B79-antibodies-05-00012],[@B80-antibodies-05-00012]\].

Anti-β~2~GP1 antibodies might be naturally occurring antibodies, as benign and low affinity APL antibodies are found in 1%--5% of healthy individuals \[[@B3-antibodies-05-00012],[@B81-antibodies-05-00012]\]. The mechanism(s) of transition of anti-β~2~GP1 antibody from benign to pathogenic are unknown, however there is evidence to suggest that this may be induced by infection. β~2~GP1 binds to pathogenic phospholipids such as protein H from *Streptococcus pyogenes* \[[@B82-antibodies-05-00012]\], causing conformational change, exposure of the cryptic epitope, and inducing production of pathogenic anti-DI-β~2~GP1 antibodies. The conformation of β~2~GP1 is also susceptible to many factors and may trigger the synthesis of antibodies. Similarly, antibody production can be prompted by ageing, vaccination, drugs, and malignancies. Their association with clinical manifestations, however, requires further investigation \[[@B2-antibodies-05-00012],[@B73-antibodies-05-00012]\].

3.3. The Two Hit Hypothesis {#sec3dot3-antibodies-05-00012}
---------------------------

The detection of anti-β~2~GP1 antibodies in healthy individuals \[[@B3-antibodies-05-00012],[@B4-antibodies-05-00012]\], APS, and SLE patients without complications \[[@B83-antibodies-05-00012]\] indicates that the antibody alone is insufficient for the pathogenesis of APS. It is proposed that a "first-hit" injury primes the endothelium, and a "second-hit" injury triggers thrombus formation. Studies have shown that anti-β~2~GP1 antibodies infused into mice only initiate thrombus formation following vessel-wall injury \[[@B84-antibodies-05-00012],[@B85-antibodies-05-00012]\]. Endothelium priming involves vessel-wall injury, infection, recent surgery \[[@B86-antibodies-05-00012]\], and rarely, the disturbance of redox balance in the vascular milieu \[[@B53-antibodies-05-00012]\]. Once primed, the "second-hit" injury, such as smoking, immobilisation, pregnancy, malignancy, *etc.*, stimulates the development of thrombosis \[[@B87-antibodies-05-00012]\].

3.4. Types of Anti-β~2~GP1 Antibodies {#sec3dot4-antibodies-05-00012}
-------------------------------------

The two hit hypothesis has been proposed to be a good model for the pathogenesis of APS \[[@B4-antibodies-05-00012]\]. Yet, it cannot clarify why APL antibodies present in healthy individuals are not pathogenic. Some studies suggest that this could be due to differences in the targeted epitope \[[@B10-antibodies-05-00012],[@B48-antibodies-05-00012]\] and the structure of anti-β~2~GP1 antibodies \[[@B4-antibodies-05-00012]\]. Anti-β~2~GP1 antibodies isolated from primary APS patients are considered to be poly-reactive, as they have been found to react against several domains of β~2~GP1, such as DV (52.9%--64.6%), DIV (45.8%), DI--II (33.1%), and DIII (20.5%) \[[@B88-antibodies-05-00012]\]. Anti-DI-β~2~GP1 antibodies recognising the cryptic epitope of DI (Type A) in symptomatic APS patients are strongly associated with thrombotic history and positive LAC activity \[[@B10-antibodies-05-00012]\]. Conversely, antibodies that are directed against other domains (Type B) in healthy populations are weakly correlated with thrombosis. These more benign type B antibodies also have lower avidity compared to those pathogenic type A antibodies \[[@B89-antibodies-05-00012]\].

Besides binding epitopes, anti-β~2~GP1 antibodies can be classified according to immunoglobulin (Ig) isotype; *i.e.*, IgG, IgM, and IgA. Among these, anti-β~2~GP1 IgG antibodies are more strongly associated with the manifestations of APS \[[@B1-antibodies-05-00012]\]. Furthermore, different subclasses of anti-β~2~GP1 IgG antibodies, predominantly IgG2 and IgG3, have also been identified in APS patients and healthy children, respectively \[[@B4-antibodies-05-00012]\]. IgG3 is the most effective activator for the classical complement pathway, hence leading to increased C3c (a complement component) activation and binding to anti-β~2~GP1 IgG3 antibodies in healthy children \[[@B4-antibodies-05-00012]\]. Complement activation normally triggers platelet activation, which is related to the pathogenesis of APS \[[@B90-antibodies-05-00012],[@B91-antibodies-05-00012]\]. However, C3c is an opsonin to improve the clearance of the bound target \[[@B92-antibodies-05-00012]\]. Instead of activating platelets, C3c binding enhances the clearance of pathogenic anti-β~2~GP1 immune complexes and protects healthy children from complications. Moreover, anti-β~2~GP1 antibodies in healthy and asymptomatic individuals are highly sialylated compared to symptomatic patients \[[@B4-antibodies-05-00012]\]. These sialylated anti-β~2~GP1 antibodies have been found to have protective roles for healthy individuals because of their inability to bind and activate platelets.

3.5. Anti-DI-β~2~GP1 Antibodies as a Diagnostic Tool {#sec3dot5-antibodies-05-00012}
----------------------------------------------------

Anti-DI-β~2~GP1 antibodies are highly associated with both vascular and obstetric complications, compared to antibodies against other domains of β~2~GP1 \[[@B10-antibodies-05-00012]\]. Anti-DI-β~2~GP1 antibodies are regularly isolated from APS patients compared to those with infection-induced transient APL antibody positivity. APS patients at higher risk of complications (triple APL positivity) also have higher titres of anti-DI-β~2~GP1 antibodies \[[@B93-antibodies-05-00012]\], suggesting that the specificity of diagnosis of APS may increase when anti-DI-β~2~GP1 antibodies are included. However, assays that detect anti-DI-β~2~GP1 antibodies have lower sensitivity compared to those that detect the whole β~2~GP1 molecule, as patients might produce clinically significant antibodies against other epitopes \[[@B46-antibodies-05-00012]\]. Currently, commercially available kits are not available for the detection of anti-DI-β~2~GP1 antibodies. Instead, research assays with different sensitivities have been reported, such as ELISAs that use N-terminally biotinylated DI on streptavidin plates \[[@B94-antibodies-05-00012]\] and a β~2~GP1-DI chemiluminescence immunoassay (CIA, INOVA Diagnostic, San Diego, CA, US) \[[@B95-antibodies-05-00012]\]. Further studies are warranted to determine the diagnostic and prognostic value of assays that detect anti-DI-β~2~GP1 antibodies.

4. Anti-β~2~GP1-β~2~GP1 Complexes and Platelets {#sec4-antibodies-05-00012}
===============================================

Although there is consensus that β~2~GP1 interacts with anti-β~2~GP1 antibodies to form anti-β~2~GP1-β~2~GP1 complexes with high affinity to anionic phospholipids \[[@B41-antibodies-05-00012],[@B48-antibodies-05-00012]\], the affected pathway(s) remains unclear. Potential mechanisms by which APL antibodies might increase the risk of vascular and obstetric complications are reviewed elsewhere \[[@B13-antibodies-05-00012]\]. In this review, we have only focused on the effects of anti-β~2~GP1 antibodies and β~2~GP1 on platelets ([Figure 2](#antibodies-05-00012-f002){ref-type="fig"}).

Platelets are a crucial component of haemostasis, a physiological process that forms a localised clot at the vessel injury site to limit blood loss while maintaining normal blood circulation \[[@B17-antibodies-05-00012],[@B102-antibodies-05-00012]\]. Activation of platelet receptors leads to platelet adhesion, aggregation, activation of the protein kinase B-mediated and/or common pathways, secretion of granules, integrin activation, synthesis of thromboxane A~2~, and finally, clot formation \[[@B17-antibodies-05-00012],[@B103-antibodies-05-00012]\]. In the patients with autoimmune diseases, circular β~2~GP1 transforms into the J-shaped conformation after binding to the phospholipid membrane of platelets, allowing anti-β~2~GP1 antibodies to bind and form anti-β~2~GP1-β~2~GP1 complexes \[[@B48-antibodies-05-00012]\] ([Figure 2](#antibodies-05-00012-f002){ref-type="fig"}). In turn, these complexes are proposed to activate platelet receptor(s)---e.g., glycoprotein (GP) Ib \[[@B14-antibodies-05-00012]\], apolipoprotein E receptor 2 (ApoER2) \[[@B16-antibodies-05-00012]\], guanine nucleotide-binding protein-coupled receptors-(GPCR) \[[@B100-antibodies-05-00012]\], and GPVI \[[@B99-antibodies-05-00012]\]. Furthermore, these complexes have also been suggested to affect other pathway(s) by inhibiting β~2~GP1 binding to vWF \[[@B15-antibodies-05-00012]\] and by interacting with platelet factor 4 (PF4) secreted from platelets \[[@B101-antibodies-05-00012]\]. The activation of platelet receptor(s) by these mechanisms potentially results in excessive clot formation and/or pregnancy complications \[[@B14-antibodies-05-00012],[@B15-antibodies-05-00012],[@B16-antibodies-05-00012]\]. Therefore, understanding the effects of anti-β~2~GP1-β~2~GP1 complexes on platelets is important not only to determine the mechanism(s) of interaction, but to also potentially assist in the development of novel or improved treatments for patients with autoimmune diseases.

It has been reported that β~2~GP1 directly binds to GPIb of the GPIb/V/IX receptor via DII--V \[[@B14-antibodies-05-00012]\]. The presence of anti-DI-β~2~GP1 antibodies potentially dimerises β~2~GP1 and inappropriately initiates GPIb-mediated platelet adhesion and aggregation \[[@B14-antibodies-05-00012],[@B104-antibodies-05-00012]\]. This activation by anti-β~2~GP1-β~2~GP1 complexes may explain the increased thrombotic risk in APS patients \[[@B14-antibodies-05-00012]\].

Besides the GPIb receptor, DV of β~2~GP1 has been shown to dimerise and interact with the A1 portion of ApoER2 \[[@B96-antibodies-05-00012],[@B97-antibodies-05-00012],[@B98-antibodies-05-00012]\]. ApoER2, also known as low-density lipoprotein receptor-related protein 8, is the only low-density lipoprotein family receptor found on platelets \[[@B96-antibodies-05-00012]\]. This receptor is recognised to be targeted by the anti-β~2~GP1-β~2~GP1 complex, as the blockage of ApoER2 by its antagonist diminishes the effect of the anti-β~2~GP1-β~2~GP1 complex to increase the adhesion of platelets to collagen \[[@B105-antibodies-05-00012]\]. It has also been established that the interaction of anti-β~2~GP1-β~2~GP1 complexes with ApoER2 activates platelet analogously to GPIb-mediated platelet activation \[[@B16-antibodies-05-00012]\]. Recently, a dimer composed of two A1 portions of ApoER2 joined by a flexible link has been created \[[@B98-antibodies-05-00012]\]. This dimer is able to inhibit anti-β~2~GP1-β~2~GP1 complexes from binding to negatively-charged phospholipids and ApoER2 \[[@B98-antibodies-05-00012]\], reflecting another possible treatment option for patients with APS.

Anti-β~2~GP1-β~2~GP1 complexes may also affect GPCR and GPVI-mediated platelet activation pathways. Anti-β~2~GP1 antibodies from different origins have recently been reported to exhibit diverse effects on *in vitro* platelet aggregation. Affinity purified rabbit \[[@B99-antibodies-05-00012]\] and SLE patient-derived anti-β~2~GP1 antibodies \[[@B100-antibodies-05-00012]\] demonstrated inhibitory and enhancement effects, respectively, on ADP-induced platelet aggregation. When collagen was used, affinity purified rabbit anti-β~2~GP1 antibodies \[[@B99-antibodies-05-00012]\] enhanced platelet aggregation. However, no effect was demonstrated using patient-derived IgG fractions (containing aCL and anti-β~2~GP1 antibodies) \[[@B106-antibodies-05-00012]\] and affinity-purified goat anti-β~2~GP1 antibodies \[[@B107-antibodies-05-00012]\]. Based on these results, it is difficult to arrive at a consensus due to the variable effects possibly caused by anti-β~2~GP1 antibodies with different structure and binding specificities. Thus, further research is needed to elucidate the variable effects of anti-β~2~GP1-β~2~GP1 complexes on GPCR- and GPVI-mediated pathways.

As described above, β~2~GP1 binds with vWF to prevent platelet activation. It has been suggested that anti-β~2~GP1 antibodies in APS patients can neutralise this inhibitory effect, potentially leading to thrombosis and consumptive thrombocytopenia \[[@B15-antibodies-05-00012]\]. Furthermore, PF4, a pro-coagulant factor secreted from the α granules of platelets, has also been demonstrated to interact with β~2~GP1 \[[@B101-antibodies-05-00012]\]. PF4 is proposed to dimerise and stabilise β~2~GP1 on phospholipids, ensuring that β~2~GP1 is easily recognised by anti-β~2~GP1 antibodies. The formation of anti-β~2~GP1-β~2~GP1-PF4 complexes may activate platelets, leading to the development of thrombosis in APS patients \[[@B101-antibodies-05-00012]\].

5. Conclusion and Further Research {#sec5-antibodies-05-00012}
==================================

There is substantial literature available on the interaction between three interchangeable β~2~GP1 structures and anti-β~2~GP1 antibodies. The transformation of S-shaped or circular β~2~GP1 to J-shaped β~2~GP1 exposes the cryptic epitope in DI, enabling the binding of anti-β~2~GP1 antibodies, particularly those to DI of β~2~GP1. The formation of the anti-β~2~GP1-β~2~GP1 complex is thought to be responsible for the increased risk of thrombosis and/or pregnancy complications in patients with autoimmune diseases. Although numerous mechanisms of interaction between anti-β~2~GP1-β~2~GP1 complex and receptors/components have been proposed, the actual affected physiological pathway(s) remain unclear. One of the possible explanations for these ambiguities is the use of anti-β~2~GP1 antibodies with different structures and binding specificities from patient- and animal-derived origins across different studies. Therefore, further research is required to better clarify and categorise the type of antibodies used. This approach will in turn facilitate studies that will lead to increased understanding of the interactions between these antibodies and platelets.

In conclusion, the standardisation and development of methods, such as anti-DI-β~2~GP1 antibody ELISAs, are required to differentiate between the types and pathogenicity of anti-β~2~GP1 antibodies. This will allow more meaningful interpretation of laboratory- and clinic-based findings, which will potentially lead to the elucidation of the mechanism(s) of interaction between β~2~GP1, anti-β~2~GP1 antibodies and platelets. In combination, these further developments can help to improve the diagnostic and therapeutic techniques for patients with APS, and perhaps more widely, autoimmune diseases.
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The following abbreviations are used in this manuscript:

APL

Anti-phospholipid

LAC

Lupus anti-coagulant

aCL

Anti-cardiolipin

Anti-β

2

GP1

Anti-beta 2 glycoprotein 1

APS

Antiphospholipid syndrome

SLE

Systemic lupus erythematosus

ELISA

Enzyme-linked immunosorbent assays

D

Domain

Anti-DI-β

2

GP1

Anti-domain I-beta 2 glycoprotein 1

EDTA

Ethylenediaminetetraacetic acid

ADP

Adenosine diphosphate

VWF

Von Willebrand factor

GP

Glycoprotein

ADAMTS13

vWF protease

Ig

Immunoglobulin

ApoER2

Apolipoprotein E receptor 2

GPCR

Guanine nucleotide-binding protein-coupled receptors

PF4

Platelet factor 4

![The interchangeable conformations of beta-2-glycoprotein 1 (β~2~GP1). β~2~GP1 is able to transform between three conformations: J-shaped, S-shaped, and circular β~2~GP1. Cryptic epitopes in S-shaped are shielded by carbohydrate chains \[[@B43-antibodies-05-00012]\]. Whereas, cryptic epitopes in circular β~2~GP1 are shielded by both carbohydrate chains and domain V \[[@B41-antibodies-05-00012],[@B44-antibodies-05-00012]\]. Binding of domain V positively charged amino acids and hydrophobic loop to phospholipid membrane breaks the shield on domain I \[[@B41-antibodies-05-00012]\]. This exposes the cryptic epitope and allows the binding of clinically significant anti-domain-I-β~2~GP1 antibody.](antibodies-05-00012-g001){#antibodies-05-00012-f001}

![Proposed mechanisms of interaction between anti-beta-2-glycoprotein 1 (β~2~GP1)-β~2~GP1 complex and platelet receptors. Circular β~2~GP1 binds to the anionic phospholipid platelet membrane and transforms into J-shaped β~2~GP1. This allows the anti-domain 1-β~2~GP1 antibody to bind and to form the anti-β~2~GP1-β~2~GP1 complex. The anti-β~2~GP1-β~2~GP1 complex has been proposed to interact with glycoprotein (GP) Ib of GPIb/V/IX \[[@B14-antibodies-05-00012]\] and apolipoprotein E receptor 2 (ApoER2) \[[@B96-antibodies-05-00012],[@B97-antibodies-05-00012],[@B98-antibodies-05-00012]\]. In our group, we propose that the complex might trigger adenosine diphosphate (ADP) and collagen-mediated pathways via guanine nucleotide-binding protein coupled receptor (GPCR) and GPVI, respectively \[[@B99-antibodies-05-00012],[@B100-antibodies-05-00012]\]. Yet, further studies are needed to clarify the variability of results. The binding of the complex with receptors leads to the activation of protein kinase B (Akt)-mediated and/or common pathways, causing granules secretion, thromboxane A~2~ (TXA~2~) synthesis, integrin activation, and subsequently, clot formation. The platelet factor 4 (PF4) from secreted α-granules have also been showed to interact with the anti-β~2~GP1-β~2~GP1 complex \[[@B101-antibodies-05-00012]\] Abbreviations: β~2~GP1, beta-2-glycoprotein 1; GP, glycoprotein; ApoER2, apolipoprotein E receptor 2; ADP, adenosine diphosphate; GPCR, guanine nucleotide-binding protein coupled receptor; TXA~2~, thromboxane A~2~; PF4, platelet factor 4; Akt, protein kinase B.](antibodies-05-00012-g002){#antibodies-05-00012-f002}
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###### 

Detection of anti-phospholipid antibodies and their clinical significance.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Assays                      Principle of Detection   Antibodies Detected                                                Clinical Significance \[[@B5-antibodies-05-00012]\]
  --------------------------- ------------------------ ------------------------------------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  LAC                         Clotting assay           LAC (mainly against β~2~GP1 and prothrombin)                       Strong correlation with thrombosis \[[@B18-antibodies-05-00012]\] and pregnancy morbidity \[[@B19-antibodies-05-00012]\].

  aCL antibody                Immunological assay      aCL antibody\                                                      Weak correlation with thrombosis and pregnancy morbidity \[[@B5-antibodies-05-00012],[@B20-antibodies-05-00012]\].Possible false positive in IgM assay caused by rheumatoid factor or cryoglobulins \[[@B21-antibodies-05-00012],[@B22-antibodies-05-00012]\].IgA assay only useful to identify patient subgroups with specific clinical manifestations \[[@B5-antibodies-05-00012]\].
                                                       (IgG, IgM, IgA)                                                    

  Anti-β~2~GP1 antibody       Immunological assay      Anti-β~2~GP1 antibody\                                             Independent risk factor for thrombosis \[[@B23-antibodies-05-00012]\] and pregnancy complications \[[@B24-antibodies-05-00012]\].Higher specificity and lower inter-laboratory variation compared to aCL assay \[[@B5-antibodies-05-00012]\].Clarifies pre-eclampsia and/or eclampsia in pregnant women with negative aCL \[[@B24-antibodies-05-00012]\].Possible false positive in IgM assay caused by rheumatoid factor or cryoglobulins \[[@B5-antibodies-05-00012]\].Presence of IgA might not associate with any clinical manifestation \[[@B5-antibodies-05-00012]\].
                                                       (IgG, IgM, IgA)                                                    

  Anti-prothrombin antibody   Immunological assay      Anti-prothrombin and anti-phosphatidylserine-prothrombin complex   May serve as a confirmatory assay for LAC \[[@B25-antibodies-05-00012]\].Association with thrombotic risk still needs to be clarified \[[@B5-antibodies-05-00012]\].
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Information collated from Miyakis *et al.* (2006) \[[@B5-antibodies-05-00012]\]. Abbreviations: LAC, lupus anti-coagulant; aCL antibody, anti-cardiolipin antibody; Ig, Immunoglobulin; anti-β~2~GP1 antibody, anti-beta 2 glycoprotein 1 antibody.
